Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 222

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 222
---
 following equity awards, warrants and free shares outstanding:

•167,460 ordinary shares issuable upon the exercise of 167,460 share warrants (BSA) outstanding as of December 31, 2024 at a weighted average exercise price of 7,84 € per ordinary share;

•1,045,722 ordinary shares issuable upon the exercise of 1,045,722 redeemable share warrants (BSAAR) outstanding as of December 31, 2024 at an exercise price of 7,20 € per ordinary share;

•755,240 ordinary shares issuable upon conversion of 6,248 free preferred shares (AGAP 2016) outstanding as of December 31, 2024; 1

•618,760 ordinary shares issuable upon the vesting of 618,760 free shares (AGA) as of December 31, 2024;

1 This section does not take into account the AGAP 2016 that can no longer be converted by their holders due to the failure to meet the presence requirement, resulting in 6,248 exercisable AGAP 2016 out of the 6,494 granted.

•1,622,500 ordinary shares issuable upon definitive acquisition of 1,622,500 free performance shares 2022 (AGA de Performance 2022), assuming all performance and presence conditions are met;

•2,023,750 ordinary shares issuable upon definitive acquisition of 2,023,750 free performance shares 2023 (AGA de Performance 2023), assuming all performance and presence conditions are met;

•2,287,900 ordinary shares issuable upon definitive acquisition of 2,287,900 free performance shares 2024 (AGA de Performance 2024), assuming all performance and presence conditions are met; and

•100,000 ordinary shares issuable upon the exercise of 100,000 stock options outstanding as of December 31, 2024 at a weighted average exercise price of €2.18 per ordinary share.

Equity Warrants and Redeemable Share Subscription Warrants

Share Warrants (BSA)

Share warrants (BSA) are issued at ade minimi s price and entitle the holder of one BSA to exercise the warrant for one underlying share, at an exercise price per share determined by the Executive Board of the Company at the time of issue by reference to the then prevailing share price. The Company has issued BSA to Supervisory Board members and certain consultants of the Company